Roxee Medication Guide

Dexamethasone

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Tablet (Chewable) Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Aug 6, 2026, 7:47 p.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Aug 6, 2026, 7:47 p.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Aug 6, 2026, 7:49 p.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Illustration placeholder

Dexamethasone

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Tablet (Chewable) Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Dexamethasone

In treatment of dogs as an anti-inflammatory agent. In treatment of cats as an anti-inflammatory agent. The drug is indicated for the treatment of primary bovine ketosis. Species commonly shown: Both, Dog, Restricted During Pregnancy, Dog.

Generic name

Dexamethasone

Brand names

Pet Derm® III Tablets, Dexamethasone Solution, Dexium®, Dexium-SP™

Manufacturer

Multiple FDA labelers

Species

Both, Dog, Horse, Cat

Dosage forms

Tablet (Chewable), Liquid (Solution), Injectable Solution, Tablet

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Pet Derm® III Tablets Dexamethasone Solution Dexium® Dexium-SP™ Dexamethasone Injection Azium® Solution Zonometh Solution Azium® Tablets 0.25 mg Azium® Aqueous Suspension Veterinary Azium® Powder Azium® Boluses 10 mg Azium® Oral Solution 2 mg Dexium™ Tablets Dexamethasone Sodium Phosphate Inj. Dex-A-Vet Injection Dexameth-A-Vet Injection Dexameth-A-Vet Dexamethasone Sterile Solution Dexachel Dexamethasone Acetate Anhydrous DEXAMETHASONE Dexamethasone SP Dexium DEXASONE Dexium-SP

Dosage forms

Tablet (Chewable) Liquid (Solution) Injectable Solution Tablet Powder Bolus Liquid

Indications / Uses

In treatment of dogs as an anti-inflammatory agent. In treatment of cats as an anti-inflammatory agent. The drug is indicated for the treatment of primary bovine ketosis.

Warnings / Contraindications

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy; and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infections. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food.

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy; and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infections. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Anaphylaxis, Death, Facial swelling (see also 'Skin').

FAQ

Both, Dog, Restricted During Pregnancy, Dog, Horse, Not For Meat Production, Cat, Horse

Yes. Roxee shows this as prescription-only.

Tablet (Chewable), Liquid (Solution), Injectable Solution, Tablet

Related Conditions

Congestive heart failure Dystocia Lameness (undifferentiated) Metritis

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://www.accessdata.fda.gov/spl/data/20cf9a39-c15c-4f19-91c5-d40aec5199bc/20cf9a39-c15c-4f19-91c5-d40aec5199bc.xml
Last refreshed: Aug 6, 2026, 7:47 p.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy
and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis
Do not use in viral infections
Anti-inflammatory action of corticosteroids may mask signs of infections
Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis
Not for use in horses intended for food
Diabetic ketoacidosis (1 reports)
Diabetes mellitus (1 reports)
Dermatitis (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Dexamethasone; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2026-US-013537

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 22 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2026-US-013537

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2026-US-013537

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Diabetic ketoacidosis (1 reports), Diabetes mellitus (1 reports), Dermatitis (1 reports), Dermal thickening (1 reports), Decreased pulse oxygenation (1 reports)

Body systems represented Signal grouping

Digestive (4), Neurologic (1), Behavior (2), Other (25)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (21 reports), Cat (11 reports)

Breed metadata in reports Metadata only

Shih Tzu (1), Siamese (1), Domestic Shorthair (1), ['Retriever - Labrador', 'Poodle (unspecified)'] (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Dexamethasone fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Clinical and experimental data have demonstrated that corticosteroids administered orally or by inje, and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta,, Do not use in viral infections, Anti-inflammatory action of corticosteroids may mask signs of infections, Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, e

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Dexamethasone brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2026-US-013537 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
SPL · document · documents
FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Zonometh Solution · official_label
openFDA case USA-USFDACVM-2026-US-013537 · adverse_reaction

Safety & side effects

Side effects to monitor:

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy
and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis
Do not use in viral infections
Anti-inflammatory action of corticosteroids may mask signs of infections
Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy

Most reported reactions:

Diabetic ketoacidosis (1 reports)
Diabetes mellitus (1 reports)
Dermatitis (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Cat, Dog, Horse

Indication / use

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Form / route / dose

Form: Bolus, Injectable Solution, Liquid, Liquid (Solution), Powder, Tablet, Tablet (Chewable)
Route: Intramuscular, Intravenous, Oral
Confirm product label and patient-specific plan.

Warnings

High: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals ma…

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA labelers

Form: Bolus, Injectable Solution, Liquid, Liquid (Solution), Powder, Tablet

Identifiers:

ANADA: 200108 ANADA: 200312 ANADA: 200317 ANADA: 200324 ANADA: 200456 ANADA: 200565 NADA: 104606 NADA: 108687 NADA: 110046 NADA: 110349 NADA: 110350 NADA: 111369 NADA: 11885 NADA: 11901 NADA: 123815 NADA: 12559 NADA: 128089 NADA: 130660 NADA: 141598 NADA: 30136

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200317 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200456 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

High: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy; and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infections. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Vomiting (7) Lethargy (see also Central nervous system depression in Neurological) (6) Emesis (multiple) (5) Gait abnormality (5) Other (26) Digestive (14) Skin & allergy (9) Neurologic (8)

Showing up to 50 matching reports.

USA-USFDACVM-2026-US-014246

Received 2026-03-24 · MSK · MSK

Non-serious

Species: Dog
Breed: Shih Tzu
Size / weight: Under 10 lb (2.49 Kilogram)
Age: Under 1 year (16 Week)
Sex: Female Intact
Region: USA
Reactions: Facial swelling (see also Skin)Vomiting
Body systems: Skin & allergyDigestive
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-014239

Received 2026-03-24 · MSK · MSK

Non-serious

Species: Cat
Breed: Siamese
Size / weight: 10-24 lb (5.65 Kilogram)
Age: 8+ years (1 Year)
Sex: Male Neutered
Region: USA
Reactions: Lack of efficacy - NOS
Body systems: Effectiveness
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-013996

Received 2026-03-24 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (3.3 Kilogram)
Age: 8+ years (18 Year)
Sex: Female Unknown
Region: USA
Reactions: Gait abnormalityWalking difficultyDecreased appetite
Body systems: OtherDigestive
Outcomes: Ongoing

USA-USFDACVM-2026-US-014100

Received 2026-03-18 · MSK · MSK

Non-serious

Species: Dog
Breed: ['Retriever - Labrador', 'Poodle (unspecified)']
Size / weight: 25-49 lb (11.7 Kilogram)
Age: 8+ years (8.08 Year)
Sex: Female Neutered
Region: USA
Reactions: HypoalbuminaemiaNeutropenia
Body systems: Other
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-013537

Received 2026-03-16 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Longhair
Size / weight: Under 10 lb (4.47 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Neutered
Region: USA
Reactions: Localised hair lossReddening of the skinItchy skinWoundDermal thickeningAbnormal cytologyIntentional misuseLocal swelling (not application site)Reverse sneezingLeukocytosis NOSThrombocytopeniaNeutrophiliaMonocytosisSkin lesion NOS
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-012576

Received 2026-03-16 · MSK · MSK

Serious

Species: Dog
Breed: Bulldog - French
Size / weight: 25-49 lb (12.791 Kilogram)
Age: 4-7 years (7 Year)
Sex: Female Neutered
Region: USA
Reactions: Lethargy (see also Central nervous system depression in Neurological)Decreased appetiteLimpingFeverSwollen lymph nodeWeight lossPolyuriaPolydipsiaEmesis (multiple)Nasal dischargeLaboured breathingStridor (Upper respiratory; for lower respiratory see also Bronchial rale)Gait abnormalityJoint painJoint effusionImmune-mediated polyarthritisLymphopeniaHypoalbuminaemiaElevated globulinsElevated aspartate aminotransferase (AST)Elevated serum alkaline phosphatase (ALP)
Body systems: NeurologicDigestiveOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-012110

Received 2026-03-16 · MSK · MSK

Non-serious

Species: Dog
Breed: Shar Pei
Size / weight: 50-99 lb (32.7 Kilogram)
Age: 8+ years (11 Year)
Sex: Female Neutered
Region: USA
Reactions: ArthritisDecreased appetiteHigh sodium-potassium ratio (Na:K ratio)VomitingDiarrhoeaGait abnormalityAppetite disorder NOSStiffness NOSNot defecatingWeight lossDysorexiaHair loss NOSWeaknessMuscle wastingDistension of abdomenPolyuriaDehydrationShakingShiveringTremorGreasy skinHair sheddingAnxiety
Body systems: OtherDigestiveSkin & allergyNeurologicBehavior
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-012730

Received 2026-03-13 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund (unspecified)
Size / weight: 10-24 lb (7.62 Kilogram)
Age: 8+ years (12 Year)
Sex: Female Unknown
Region: USA
Reactions: EmesisLack of efficacy - NOS
Body systems: DigestiveEffectiveness
Outcomes: Recovered/Normal

USA-USFDACVM-2026-US-011643

Received 2026-03-12 · MSK · MSK

Non-serious

Species: Dog
Breed: Spitz - German Pomeranian
Size / weight: Under 10 lb (3.357 Kilogram)
Age: 8+ years (12 Year)
Sex: Female Unknown
Region: USA
Reactions: Unable to standHead downNot drinkingReluctant to moveIntentional misuse
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2026-US-011341

Received 2026-03-05 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (4.881 Kilogram)
Age: 4-7 years (5 Year)
Sex: Female Unknown
Region: USA
Reactions: VomitingAnorexiaDecreased bowel movementsElevated liver enzymes NOSIntentional misuse
Body systems: DigestiveOther
Outcomes: Ongoing

USA-USFDACVM-2026-US-009056

Received 2026-02-26 · MSK · MSK

Serious

Species: Dog
Breed: Terrier - Bull - American Pit
Size / weight: 50-99 lb (28.49 Kilogram)
Age: 8+ years (8.42 Year)
Sex: Female Unknown
Region: USA
Reactions: Weight lossLethargy (see also Central nervous system depression in Neurological)Limb weakness
Body systems: OtherNeurologic
Outcomes: Ongoing

USA-USFDACVM-2026-US-008346

Received 2026-02-23 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (4.4 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Neutered
Region: USA
Reactions: MonocytosisLow creatinineGait abnormalityMuscle atrophy (see also Muscle wasting)Unkempt hair coatPlantigrade postureSedationGreasy skin
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2026-US-011611

Received 2026-02-14 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (6.3 Kilogram)
Age: 4-7 years (6 Year)
Sex: Male Neutered
Region: USA
Reactions: DeathDullNot himself/herselfHead pressingHypotensionUnresponsive to stimuli
Body systems: Other
Outcomes: Died

USA-USFDACVM-2026-US-005003

Received 2026-02-04 · MSK · MSK

Serious

Species: Dog
Breed: Rottweiler
Size / weight: 50-99 lb (4 Kilogram)
Age: 8+ years (1 Year)
Sex: Female Unknown
Region: USA
Reactions: Addison's diseaseLethargy (see also Central nervous system depression in Neurological)FebrileDecreased pulse oxygenationAspiration pneumoniaHypotensionElevated lactateHind limb paresisReduced reflexesDeath
Body systems: OtherNeurologic
Outcomes: Died

USA-USFDACVM-2026-US-005800

Received 2026-02-02 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (6.3 Kilogram)
Age: 4-7 years (6 Year)
Sex: Male Neutered
Region: USA
Reactions: DeathDullNot himself/herselfHead pressingHypotensionUnresponsive to stimuli
Body systems: Other
Outcomes: Died

USA-USFDACVM-2026-US-003405

Received 2026-01-16 · MSK · MSK

Non-serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (4.39 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Neutered
Region: USA
Reactions: Balance problemPlantigrade postureLimpingWobblinessMonocytosisGait abnormality
Body systems: Other
Outcomes: Outcome Unknown

USA-USFDACVM-2026-US-001079

Received 2026-01-16 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: Under 10 lb (4.395 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Unknown
Region: USA
Reactions: LimpingWobblinessMonocytosisLow creatinineSedationUnkempt hair coatGreasy skinPlantigrade postureMuscle atrophy (see also Muscle wasting)Medication error NOS
Body systems: Other
Outcomes: Ongoing

USA-USFDACVM-2025-US-075387

Received 2025-12-23 · MSK · MSK

Serious

Species: Dog
Breed: ['Shepherd Dog - Australian', 'Poodle (unspecified)']
Size / weight: 50-99 lb (24.131 Kilogram)
Age: 1-3 years (2 Year)
Sex: Male Neutered
Region: USA
Reactions: PolyuriaSoft stoolVomiting
Body systems: OtherDigestive
Outcomes: Ongoing

USA-USFDACVM-2025-US-074361

Received 2025-12-18 · MSK · MSK

Serious

Species: Dog
Breed: ['Terrier - Jack Russell', 'Terrier - Bull - American Pit']
Size / weight: 25-49 lb (17.236 Kilogram)
Age: 1-3 years (1 Year)
Sex: Female Unknown
Region: USA
Reactions: Emesis (multiple)Hives (see also Skin)Reddening of the skinSkin irritationUrine leakageHypersensitivity reaction
Body systems: DigestiveSkin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-074459

Received 2025-12-16 · MSK · MSK

Serious

Species: Dog
Breed: Retriever - Labrador
Size / weight: 50-99 lb (33.339 Kilogram)
Age: 8+ years (8 Year)
Sex: Female Unknown
Region: USA
Reactions: Immune mediated haemolytic anaemiaDeathAnaemia NOSThrombocytopeniaNeutrophiliaHeart murmurVomitingIcterusPantingNot eatingOther abnormal test result NOSElevated alanine aminotransferase (ALT)Elevated total bilirubinElevated serum alkaline phosphatase (ALP)ThrombocytosisHaemolysis NOSMedication error NOSMonocytosisLarge plateletsSpherocytosisAgglutination test, positive
Body systems: OtherDigestive
Outcomes: Died

USA-USFDACVM-2025-US-074693

Received 2025-12-12 · MSK · MSK

Serious

Species: Dog
Breed: Shih Tzu
Size / weight: 10-24 lb (6.53 Kilogram)
Age: 8+ years (11.68 Year)
Sex: Female Neutered
Region: USA
Reactions: Not eatingPeriorbital oedemaFeverLocal swelling (not application site)Nasal dischargeStridor (Upper respiratory; for lower respiratory see also Bronchial rale)Face and neck swelling (see also Skin)SneezingRespiratory tract disorder NOSBiting -aggression (see also Skin and appendages disorders)
Body systems: OtherSkin & allergyBehavior
Outcomes: Ongoing

USA-USFDACVM-2025-US-074149

Received 2025-12-12 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund - Miniature
Size / weight: Under 10 lb (2.812 Kilogram)
Age: 1-3 years (1 Year)
Sex: Female Intact
Region: USA
Reactions: Circulatory collapse (see also Neurological and Systemic disorders)Pale mucous membraneEmesis (multiple)Hives (see also Skin)Anaphylaxis
Body systems: NeurologicOtherDigestiveSkin & allergy
Outcomes: Ongoing

USA-USFDACVM-2025-US-073798

Received 2025-12-08 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (4.536 Kilogram)
Age: 4-7 years (5 Year)
Sex: Male Neutered
Region: USA
Reactions: LimpingWeight lossParalysis NOS
Body systems: Other
Outcomes: Outcome Unknown

USA-USFDACVM-2025-US-071120

Received 2025-12-01 · MSK · MSK

Non-serious

Species: Cat
Breed: Maine Coon
Size / weight: 10-24 lb (5.942 Kilogram)
Age: 8+ years (8 Year)
Sex: Male Unknown
Region: USA
Reactions: Pain NOSLamenessNot eatingFeverHigh pancreatic-specific lipaseLethargy (see also Central nervous system depression in Neurological)VomitingLack of efficacy - NOS
Body systems: OtherNeurologicDigestiveEffectiveness
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-070459

Received 2025-11-25 · MSK · MSK

Serious

Species: Dog
Breed: Dachshund - Miniature
Size / weight: 10-24 lb (5.557 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Unknown
Region: USA
Reactions: Emesis (multiple)Lateral recumbencyPale mucous membraneDry mucous membraneAnaphylaxisHives (see also Skin)Swollen muzzle
Body systems: DigestiveOtherSkin & allergy
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-068758

Received 2025-11-21 · MSK · MSK

Serious

Species: Dog
Breed: ['Sheepdog (unspecified)', 'Poodle (unspecified)']
Size / weight: 100+ lb (49.895 Kilogram)
Age: 4-7 years (4 Year)
Sex: Male Neutered
Region: USA
Reactions: Injection site swellingAbnormal cytologyInjection site abscessPainful urinationVocalisationBlood in urineUrinary tract infectionElevated temperatureMedication error NOS
Body systems: Skin & allergyOther
Outcomes: Ongoing

USA-USFDACVM-2025-US-070899

Received 2025-11-20 · MSK · MSK

Serious

Species: Cat
Breed: Domestic Shorthair
Size / weight: 10-24 lb (6.713 Kilogram)
Age: 8+ years (10.4 Year)
Sex: Female Neutered
Region: USA
Reactions: Dry mucous membraneNot eatingLethargy (see also Central nervous system depression in Neurological)Fever
Body systems: OtherNeurologic
Outcomes: Recovered/Normal

USA-USFDACVM-2025-US-069329

Received 2025-11-17 · MSK · MSK

Serious

Species: Cat
Breed: ['Siamese', 'Cat (other)']
Size / weight: 10-24 lb (5.352 Kilogram)
Age: 4-7 years (4 Year)
Sex: Female Unknown
Region: USA
Reactions: AnaphylaxisPantingOpen mouth breathingElevated temperatureEmesis (multiple)HidingLethargy (see also Central nervous system depression in Neurological)Low blood pressureFacial swelling (see also Skin)Local erythema
Body systems: OtherDigestiveNeurologicSkin & allergy
Outcomes: Ongoing

USA-USFDACVM-2025-US-067552

Received 2025-11-13 · MSK · MSK

Serious

Species: Dog
Breed: Shepherd Dog - German
Size / weight: 50-99 lb (40.37 Kilogram)
Age: 8+ years (9 Year)
Sex: Male Neutered
Region: USA
Reactions: Injection site painNot himself/herselfVomitingWobblinessUnexplained death
Body systems: OtherDigestive
Outcomes: Died

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (4) · Loss of appetite, Diarrhea, Decreased appetite Neurologic (1) · Unsteady walking (ataxia) Behavior (2) · Biting -aggression, Anxiety Other (25) · Diabetic ketoacidosis, Diabetes mellitus, Dermatitis

Most Reported Reactions

Body system	Cases	Species	Serious cases
Other	1	Cat	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Cat	1

Species coverage: Dog (21) Cat (11)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Neurologic	Cat	Non-serious	-	1
Digestive	Cat	Non-serious	-	1
Digestive	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Digestive	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Behavior	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Digestive	Dog	Non-serious	-	1
Behavior	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2026-US-013537

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Dexium-SP™ SPL · SPL Dexamethasone Solution SPL · SPL Zonometh Solution SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

No official label or package insert links yet.

SPL

FOI

Dexium-SP™

SPL · SPL

Open original

FDA Structured Product Label

Dexium-SP™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
ANADA: 200-317
Status: RX
Form: Injectable Solution
Route: Intravenous

Composition / specifications

Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosage

The drug is administered intravenously at a dosage of 2.5 to 5.0 milligrams. If permanent corticosteroid effect is required, oral therapy may be substituted. When therapy is withdrawn after prolonged use, the daily dose should be reduced gradually over several days.

Limitations

Dexamethasone Solution

SPL · SPL

Open original

FDA Structured Product Label

Dexamethasone Solution

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Med-Pharmex, Inc.
ANADA: 200-456
Status: RX
Form: Injectable Solution
Route: Intravenous, Intramuscular

Composition / specifications

Each milliliter of solution contains 2 milligrams dexamethasone.

Cattle

Indication

For the treatment of primary bovine ketosis and as an anti-inflammatory agent.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication

For use as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Zonometh Solution

SPL · SPL

Open original

FDA Structured Product Label

Zonometh Solution

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Huvepharma EOOD
NADA: 128-089
Status: RX
Form: Liquid (Solution)
Route: Intravenous, Intramuscular
Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone

Dogs

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly.

Limitations

Cats

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly.

Limitations

Horses

Indication

The drug is used as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly.

Limitations

Dexameth-A-Vet

SPL · SPL

Open original

FDA Structured Product Label

Dexameth-A-Vet

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
NADA: 99607
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Horse

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains either 2.0 milligrams of dexamethasone or 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams of dexamethasone).

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent.

Dosage

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dexameth-A-Vet Injection

SPL · SPL

Open original

FDA Structured Product Label

Dexameth-A-Vet Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
NADA: 99606
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Dog

Composition / specifications

Dogs

Indication

The drug is used in dogs for the treatment of inflammatory conditions, as supportive therapy in canine posterior paresis, as supportive therapy before or after surgery to enhance recovery of poor surgical risks, and as supportive therapy in nonspecific dermatosis.

Dosage

The drug is administered intravenously at 0.25 to 1 milligram initially. The dose may be repeated for 3 to 5 days or until a response is noted. If continued treatment is required, oral therapy may be substituted. When therapy is withdrawn after prolonged use, the daily dose should be reduced gradually over several days.

Limitations

Dex-A-Vet Injection

SPL · SPL

Open original

FDA Structured Product Label

Dex-A-Vet Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
NADA: 99604
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Horse

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams of dexamethasone).

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosage

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dex-A-Vet Injection

SPL · SPL

Open original

FDA Structured Product Label

Dex-A-Vet Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
NADA: 99605
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Dog

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

Dogs

Indication

Dosage

Limitations

Dexium®

SPL · SPL

Open original

FDA Structured Product Label

Dexium®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
ANADA: 200-312
Status: RX
Form: Liquid (Solution)
Route: Intramuscular, Intravenous
Species: Dog • Horse • Cat

Composition / specifications

Each milliliter contains 2 milligrams of dexamethasone.

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cattle

Indication

The drug is indicated as an anti-inflammatory agent in cattle.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cats

Indication

The drug is indicated as an anti-inflammatory agent in cats.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Dogs

Indication

The drug is indicated as an anti-inflammatory agent in dogs.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Dexium™ Tablets

SPL · SPL

Open original

FDA Structured Product Label

Dexium™ Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Bimeda Animal Health Ltd.
NADA: 95218
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

Each tablet contains 0.25 milligram of dexamethasone.

Cats

Indication

Dexamethasone is indicated for use as an anti-inflammatory agent

Dosage

Administer orally at 0.125 to 0.5 mg. per day up to 7 days

Limitations

Do not use in viral infections. Except for emergency therapy, do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome and peptic ulcers. Existence of congestive heart failure, diabetes and osteoporosis are relative contraindications. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Additionally, corticosteroids administered to dogs, rabbits and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies including deformed forelegs, phocomelia and anasarca.

Dogs

Indication

Dexamethasone is indicated for use as an anti-inflammatory agent

Dosage

Administer orally at 0.25 to 1.25 mg. per day up to 7 days

Limitations

Dexamethasone Injection

SPL · SPL

Open original

FDA Structured Product Label

Dexamethasone Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Watson Laboratories, Inc.
NADA: 104-606
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Dog • Horse

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

Dogs

Indication

The drug is used in dogs for the treatment of inflammatory conditions, as supportive therapy in canine posterior paresis as supportive therapy before or after surgery to enhance recovery of poor surgical risks, and as supportive therapy in nonspecific dermatosis.

Dosage

Limitations

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosage

Limitations

Dexamethasone Solution

SPL · SPL

Open original

FDA Structured Product Label

Dexamethasone Solution

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Huvepharma EOOD
ANADA: 200-108
Status: RX
Form: Liquid (Solution)
Route: Intravenous, Intramuscular
Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2 milligrams of dexamethasone.

Cats

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Horses

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Dogs

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

0.25 to 1 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Cattle

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

5 to 20 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Dexamethasone Sterile Solution

SPL · SPL

Open original

FDA Structured Product Label

Dexamethasone Sterile Solution

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Kinetic Technologies, LLC
NADA: 111-369
Status: RX
Form: Liquid (Solution)
Route: Intravenous, Intramuscular
Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone

Dogs

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.25 to 1 milligram administered intravenously or intramuscularly.

Limitations

Cats

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly.

Limitations

Horses

Indication

The drug is used as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly.

Limitations

Pet Derm® III Tablets

SPL · SPL

Open original

FDA Structured Product Label

Pet Derm® III Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Kinetic Technologies, LLC
NADA: 108-687
Status: RX
Form: Tablet (Chewable)
Route: Oral
Species: Dog

Composition / specifications

Each half-scored tablet contains 0.25 milligrams of dexamethasone.

Dogs

Indication

Supportive therapy in nonspecific dermatosis and inflammatory conditions.

Dosage

0.25 to 1.25 milligrams per day. Administer by free-choice feeding or crumble over food. Administer 0.25 to 1.25 milligrams daily in single or two divided doses until response is noted or 7 days have elapsed. When response is attained, dosage should be gradually reduced by 0.125 milligram per day until maintenance level is achieved.

Limitations

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy, and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infection. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Azium® Aqueous Suspension Veterinary

SPL · SPL

Open original

FDA Structured Product Label

Azium® Aqueous Suspension Veterinary

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Intervet, Inc.
NADA: 11901
Status: RX
Form: Liquid (Solution)
Route: Intramuscular, Intravenous
Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2 milligrams of dexamethasone.

Cattle

Indication

The drug is indicated for the treatment of primary bovine ketosis.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Cats

Indication

The drug is indicated as an anti-inflammatory agent in cats.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Dogs

Indication

The drug is indicated as an anti-inflammatory agent in dogs.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Azium® Boluses 10 mg

SPL · SPL

Open original

FDA Structured Product Label

Azium® Boluses 10 mg

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Intervet, Inc.
NADA: 30435
Status: RX
Form: Bolus
Route: Oral
Species: Horse

Composition / specifications

Each bolus is half-scored and contains 10 milligrams of dexamethasone.

Cattle

Indication

Dexamethasone bolus is indicated in cases where cattle require additional steroid therapy following its parenteral administration. The drug may be used as supportive therapy for management of inflammatory conditions such as acute arthritic lameness; and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

Dosage

Administered orally, 5 to 10 milligrams for the first day, then 5 milligrams per day as required.

Limitations

Do not use in viral infections during the viremic stage. With bacterial infections, appropriate antibacterial therapy should be used. Do not use in animals with chronic nephritis and hypercorticalism (cushingoid syndrome) except for emergency therapy. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Horses

Indication

Dexamethasone bolus is indicated in cases where horses require additional steroid therapy following its parenteral administration. The drug may be used as supportive therapy for management of inflammatory conditions such as acute arthritic lameness es; and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

Dosage

Administered orally, 5 to 10 milligrams for the first day, then 5 milligrams per day as required.

Limitations

Azium® Oral Solution 2 mg

SPL · SPL

Open original

FDA Structured Product Label

Azium® Oral Solution 2 mg

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Intervet, Inc.
NADA: 92835
Status: RX
Form: Liquid
Route: Oral
Species: Dog • Horse • Cat

Azium® Powder

SPL · SPL

Open original

FDA Structured Product Label

Azium® Powder

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Intervet, Inc.
NADA: 30434
Status: RX
Form: Powder
Route: Oral
Species: Horse

Composition / specifications

Dexamethasone powder is packaged in packets containing 10 milligrams of dexamethasone.

Cattle

Indication

Dexamethasone powder is indicated in cases where cattle require additional steroid therapy following its parenteral administration. The drug is used as supportive therapy for management or inflammatory conditions such as acute arthritic lameness; and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

Dosage

The drug is administered at a dosage level of 5 to 10 milligrams per animal the first day then 5 milligrams per day as required by drench or by sprinkling on a small amount of feed.

Limitations

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Horses

Indication

Dexamethasone powder is indicated in cases where horses require additional steroid therapy following its parenteral administration. The drug is used as supportive therapy for management or inflammatory conditions such as acute arthritic lameness; and for various stress conditions where corticosteroids are required while the animal is being treated for a specific condition.

Dosage

The drug is administered at a dosage level of 5 to 10 milligrams per animal the first day then 5 milligrams per day as required by drench or by sprinkling on a small amount of feed.

Limitations

Azium® Solution

SPL · SPL

Open original

FDA Structured Product Label

Azium® Solution

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Intervet, Inc.
NADA: 12559
Status: RX
Form: Liquid (Solution)
Route: Intramuscular, Intravenous
Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2 milligrams of dexamethasone.

Dogs

Indication

The drug is indicated as an anti-inflammatory agent in dogs.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cats

Indication

The drug is indicated as an anti-inflammatory agent in cats.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cattle

Indication

The drug is indicated as an anti-inflammatory agent in cattle.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Azium® Tablets 0.25 mg

SPL · SPL

Open original

FDA Structured Product Label

Azium® Tablets 0.25 mg

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Intervet, Inc.
NADA: 11885
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

Each tablet contains 0.25 milligram of dexamethasone.

Dogs

Indication

In treatment of dogs as an anti-inflammatory agent.

Dosage

Administer orally at 0.25 to 1.25 milligrams per day for up to 7 days.

Limitations

Cats

Indication

In treatment of cats as an anti-inflammatory agent.

Dosage

Administer orally at 0.125 to 0.5 milligram per day for up to 7 days.

Limitations

Dexachel

SPL · SPL

Open original

FDA Structured Product Label

Dexachel

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 130-660
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone

Dogs

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.25 to 1 milligrams administered intravenously.

Limitations

Cats

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams administered intravenously.

Limitations

Horses

Indication

The drug is used as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously.

Limitations

Dexamethasone Injection

SPL · SPL

Open original

This source does not expose a safe inline preview. Use the original source link for the full document.

Dexamethasone Injection

SPL · SPL

Open original

This source does not expose a safe inline preview. Use the original source link for the full document.

Dexamethasone Injection

SPL · SPL

Open original

FDA Structured Product Label

Dexamethasone Injection

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Sparhawk Laboratories, Inc.
ANADA: 200-324
Status: RX
Form: Liquid (Solution)
Route: Intravenous, Intramuscular
Species: Horse

Composition / specifications

Each milliliter contains 2 milligrams of dexamethasone.

Cattle

Indication

For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dexamethasone Sodium Phosphate Inj.

SPL · SPL

Open original

This source does not expose a safe inline preview. Use the original source link for the full document.

Dexamethasone Sodium Phosphate Inj.

SPL · SPL

Open original

FDA Structured Product Label

Dexamethasone Sodium Phosphate Inj.

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
NADA: 123-815
Status: RX
Form: Liquid (Solution)
Route: Intravenous
Species: Dog • Horse

Composition / specifications

Specifications: The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams of dexamethasone).

Dogs

Indication

The drug is given for glucocorticoid and anti-inflammatory agent.

Dosage

0.25 to 1 milligram initially, administered intravenously. May be repeated for 3 to 5 days or until response is noted.

Limitations

If permanent glucocorticoid effect is required, oral therapy may be substituted. When therapy is to be withdraw after prolonged use, the daily dose should be reduced gradually over several days. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of glucocorticoids may mask signs of infection. Except when used for emergency therapy, the product is contraindicated in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication

The drug is given for glucocorticoid and anti-inflammatory agent.

Dosage

FOI · FOI summary

Open original

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1065 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/156/Dexium-SP%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1176 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2572/Dexamethasone%20Solution · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/512/Zonometh%20Solution · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1924/Dexameth-A-Vet · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1919/Dexameth-A-Vet%20Injection · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1910/Dex-A-Vet%20Injection · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1918/Dex-A-Vet%20Injection · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/1060 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Aug 6, 2026, 7:47 PM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Aug 6, 2026, 7:47 PM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Aug 6, 2026, 7:52 PM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: DEXAMETHASONE DEXASONE Dexamethasone Acetate Anhydrous Dexamethasone SP Dexium Dexium-SP

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog, Horse

Rx/OTC: RX

Form/route: Bolus, Injectable Solution, Liquid, Liquid (Solution), Powder, Tablet, Tablet (Chewable) • Intramuscular, Intravenous, Oral

Applications: ANADA 200-317 • ANADA 200-456 • NADA 128-089 • NADA 99607 • NADA 99606 • NADA 99604 • NADA 99605 • ANADA 200-312 • NADA 95218 • NADA 104-606 • ANADA 200-108 • NADA 111-369 • NADA 108-687 • NADA 11901 • NADA 30435 • NADA 92835 • NADA 30434 • NADA 12559 • NADA 11885 • NADA 130-660 • NADA 110-349 • NADA 110-350 • ANADA 200-324 • NADA 110-046 • NADA 123-815

NDC: Packages 13985-043-29 13985-533-03 13985-533-25 46066-223-04 46066-223-80 50989-437-12 • Products 13985 46066 50989 57319 60270 61133

Documents: 5 (FOI: 5) • SPL: 25 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 106 • Cat 56 • View

Case summaries: 29 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Congestive heart failure Dystocia Lameness (undifferentiated) Metritis

Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes

ICD10_CM: H60.90

Otitis externa, unspecified ear

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy; and they may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of corticosteroids may mask signs of infections. Do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers, except for emergency therapy. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in horses intended for food. (Contraindication, High)

Top reaction signals

Diabetic ketoacidosis (1) Diabetes mellitus (1) Dermatitis (1) Dermal thickening (1) Decreased pulse oxygenation (1) Decreased blood urea nitrogen (BUN) or creatinine (1) Death (1) Deafness (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
0010-5587-01	0010	-
0010-5587-02	0010	-
0010-5587-03	0010	-
0010-5587-04	0010	-
13985-043-29	13985	-
13985-533-03	13985	-
13985-533-25	13985	-
46066-223-04	46066	-
46066-223-80	46066	-
50989-437-12	50989	-
57319-519-05	57319	-
60270-337-10	60270	-
61133-0892-9	61133	-
61133-0899-9	61133	-
73309-154-01	73309	-
73309-154-02	73309	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

DEXAMETHASONE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
DEXAMETHASONE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
DEXAMETHASONE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
DEXASONE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Dexium-SP SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
DEXAMETHASONE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Dexium SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Dexamethasone SP SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Dexamethasone Acetate Anhydrous SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141598
ucm061771.pdf • FOI summary • Official • April 1, 2024
FDA FOI summary for application 200317
UCM492475.pdf • FOI summary • Official • Dec. 26, 2023
FDA FOI summary for application 200456
ucm061765.pdf • FOI summary • Official • Oct. 2, 2018
FDA FOI summary for application 200312
A200108_Org_4_13_1995.pdf • FOI summary • Official • May 16, 2017
FDA FOI summary for application 200108
ucm061789.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200324
UCM457231.pdf • FOI summary • Official • June 1, 2016
FDA FOI summary for application 200565

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 135 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Diarrhoea, Anaphylaxis, Death, Facial swel… (Clinical, 2026-04-11)
contraindications: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition … (Official, 2026-04-12)
contraindications: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition … (Official, 2026-04-11)
contraindications: Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition … (Official, 2026-02-12)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-08-06)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-08-05)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-08-04)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-08-03)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-08-02)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-08-01)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-31)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-30)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-29)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-28)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-27)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-26)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-25)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-25)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-22)
indications: For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. (Official, 2026-07-22)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Dexium-SP™ RX Dexamethasone Sodium Phosphate Injectable Solution • Intravenous Label highlights Official documents	Bimeda Animal Health Ltd.	ANADA 200-317	Approved	Apr 1, 2024
Dexamethasone Solution RX Dexamethasone Injectable Solution • Intravenous, Intramuscular Label highlights Official documents	Med-Pharmex, Inc.	ANADA 200-456	W	Dec 26, 2023
Zonometh Solution RX Dexamethasone Liquid (Solution) • Intravenous, Intramuscular Label highlights Official documents	Huvepharma EOOD	NADA 128-089	Approved	Aug 7, 2019
Dexameth-A-Vet RX Dexamethasone Liquid (Solution) • Intravenous Label highlights Official documents	Bimeda Animal Health Ltd.	NADA 99607	Approved	Oct 2, 2018
Dexameth-A-Vet Injection RX Dexamethasone Liquid (Solution) • Intravenous Label highlights Official documents	Bimeda Animal Health Ltd.	NADA 99606	Approved	Oct 2, 2018
Dex-A-Vet Injection RX Dexamethasone Sodium Phosphate Liquid (Solution) • Intravenous Label highlights Official documents	Bimeda Animal Health Ltd.	NADA 99604	Approved	Oct 2, 2018
Dex-A-Vet Injection RX Dexamethasone Sodium Phosphate Liquid (Solution) • Intravenous Label highlights Official documents	Bimeda Animal Health Ltd.	NADA 99605	Approved	Oct 2, 2018
Dexium® RX Dexamethasone Liquid (Solution) • Intramuscular, Intravenous Label highlights Official documents	Bimeda Animal Health Ltd.	ANADA 200-312	Approved	Oct 2, 2018
Dexium™ Tablets RX Dexamethasone Tablet • Oral Label highlights Official documents	Bimeda Animal Health Ltd.	NADA 95218	Approved	Oct 2, 2018
Dexamethasone Injection RX Dexamethasone Sodium Phosphate Liquid (Solution) • Intravenous Label highlights Official documents	Watson Laboratories, Inc.	NADA 104-606	W	Jul 25, 2018
Dexamethasone Solution RX Dexamethasone Liquid (Solution) • Intravenous, Intramuscular Label highlights Official documents	Huvepharma EOOD	ANADA 200-108	Approved	May 16, 2017
Dexamethasone Sterile Solution RX Dexamethasone Liquid (Solution) • Intravenous, Intramuscular Label highlights Official documents	Kinetic Technologies, LLC	NADA 111-369	Approved	Nov 3, 2016
Pet Derm® III Tablets RX Dexamethasone Tablet (Chewable) • Oral Label highlights Official documents	Kinetic Technologies, LLC	NADA 108-687	Approved	Nov 3, 2016
Azium® Aqueous Suspension Veterinary RX Dexamethasone Liquid (Solution) • Intramuscular, Intravenous Label highlights Official documents	Intervet, Inc.	NADA 11901	Approved	Jun 1, 2016
Azium® Boluses 10 mg RX Dexamethasone Bolus • Oral Label highlights Official documents	Intervet, Inc.	NADA 30435	Approved	Jun 1, 2016
Azium® Oral Solution 2 mg RX Dexamethasone Liquid • Oral Official documents	Intervet, Inc.	NADA 92835	Approved	Jun 1, 2016
Azium® Powder RX Dexamethasone Powder • Oral Label highlights Official documents	Intervet, Inc.	NADA 30434	Approved	Jun 1, 2016
Azium® Solution RX Dexamethasone Liquid (Solution) • Intramuscular, Intravenous Label highlights Official documents	Intervet, Inc.	NADA 12559	Approved	Jun 1, 2016
Azium® Tablets 0.25 mg RX Dexamethasone Tablet • Oral Label highlights Official documents	Intervet, Inc.	NADA 11885	Approved	Jun 1, 2016
Dexachel RX Dexamethasone Liquid (Solution) • Intravenous Label highlights Official documents	Zoetis Inc.	NADA 130-660	Approved	Jun 1, 2016
Dexamethasone Injection RX Dexamethasone Sodium Phosphate Official documents	Watson Laboratories, Inc.	NADA 110-349	W	Jun 1, 2016
Dexamethasone Injection RX Dexamethasone Official documents	Watson Laboratories, Inc.	NADA 110-350	W	Jun 1, 2016
Dexamethasone Injection RX Dexamethasone Liquid (Solution) • Intravenous, Intramuscular Label highlights Official documents	Sparhawk Laboratories, Inc.	ANADA 200-324	Approved	Jun 1, 2016
Dexamethasone Sodium Phosphate Inj. RX Dexamethasone Sodium Phosphate Official documents	Akorn, Inc.	NADA 110-046	W	Jun 1, 2016
Dexamethasone Sodium Phosphate Inj. RX Dexamethasone Sodium Phosphate Liquid (Solution) • Intravenous Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	NADA 123-815	Approved	Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications

Each milliliter of solution contains 2 milligrams dexamethasone.

Cattle

Indication

For the treatment of primary bovine ketosis and as an anti-inflammatory agent.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication

For use as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone

Dogs

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly.

Limitations

Cats

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly.

Limitations

Horses

Indication

The drug is used as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse

Composition / specifications

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent.

Dosage

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Dogs

Indication

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams of dexamethasone).

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosage

Limitations

Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

Dogs

Indication

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

Each milliliter contains 2 milligrams of dexamethasone.

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cattle

Indication

The drug is indicated as an anti-inflammatory agent in cattle.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cats

Indication

The drug is indicated as an anti-inflammatory agent in cats.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Dogs

Indication

The drug is indicated as an anti-inflammatory agent in dogs.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each tablet contains 0.25 milligram of dexamethasone.

Cats

Indication

Dexamethasone is indicated for use as an anti-inflammatory agent

Dosage

Administer orally at 0.125 to 0.5 mg. per day up to 7 days

Limitations

Dogs

Indication

Dexamethasone is indicated for use as an anti-inflammatory agent

Dosage

Administer orally at 0.25 to 1.25 mg. per day up to 7 days

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams dexamethasone).

Dogs

Indication

Dosage

Limitations

Horses

Indication

The drug is used as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2 milligrams of dexamethasone.

Cats

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Horses

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Dogs

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

0.25 to 1 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

Cattle

Indication

The drug is indicated as an anti-inflammatory agent.

Dosage

5 to 20 milligrams depending on the severity of the condition. The drug is administered intravenously or intramuscularly and dosage may be repeated if necessary.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone

Dogs

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.25 to 1 milligram administered intravenously or intramuscularly.

Limitations

Cats

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly.

Limitations

Horses

Indication

The drug is used as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog

Composition / specifications

Each half-scored tablet contains 0.25 milligrams of dexamethasone.

Dogs

Indication

Supportive therapy in nonspecific dermatosis and inflammatory conditions.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2 milligrams of dexamethasone.

Cattle

Indication

The drug is indicated for the treatment of primary bovine ketosis.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Cats

Indication

The drug is indicated as an anti-inflammatory agent in cats.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

Dogs

Indication

The drug is indicated as an anti-inflammatory agent in dogs.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly; the dosage may be repeated if necessary.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse

Composition / specifications

Each bolus is half-scored and contains 10 milligrams of dexamethasone.

Cattle

Indication

Dosage

Administered orally, 5 to 10 milligrams for the first day, then 5 milligrams per day as required.

Limitations

Horses

Indication

Dosage

Administered orally, 5 to 10 milligrams for the first day, then 5 milligrams per day as required.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse

Composition / specifications

Dexamethasone powder is packaged in packets containing 10 milligrams of dexamethasone.

Cattle

Indication

Dosage

The drug is administered at a dosage level of 5 to 10 milligrams per animal the first day then 5 milligrams per day as required by drench or by sprinkling on a small amount of feed.

Limitations

Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Federal law restricts this drug to use by or on the order of a licensed veterinarian. A withdrawal period has not been established for this product in pre-ruminating calves. Do not use in calves to be processed for veal.

Horses

Indication

Dosage

The drug is administered at a dosage level of 5 to 10 milligrams per animal the first day then 5 milligrams per day as required by drench or by sprinkling on a small amount of feed.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2 milligrams of dexamethasone.

Dogs

Indication

The drug is indicated as an anti-inflammatory agent in dogs.

Dosage

0.25 to 1 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cats

Indication

The drug is indicated as an anti-inflammatory agent in cats.

Dosage

0.125 to 0.5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Cattle

Indication

The drug is indicated as an anti-inflammatory agent in cattle.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each tablet contains 0.25 milligram of dexamethasone.

Dogs

Indication

In treatment of dogs as an anti-inflammatory agent.

Dosage

Administer orally at 0.25 to 1.25 milligrams per day for up to 7 days.

Limitations

Cats

Indication

In treatment of cats as an anti-inflammatory agent.

Dosage

Administer orally at 0.125 to 0.5 milligram per day for up to 7 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse • Cat

Composition / specifications

The drug is a sterile aqueous solution. Each milliliter contains 2.0 milligrams of dexamethasone

Dogs

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.25 to 1 milligrams administered intravenously.

Limitations

Cats

Indication

The drug is used as an anti-inflammatory agent.

Dosage

0.125 to 0.5 milligrams administered intravenously.

Limitations

Horses

Indication

The drug is used as an anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse

Composition / specifications

Each milliliter contains 2 milligrams of dexamethasone.

Cattle

Indication

For the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle.

Dosage

5 to 20 milligrams depending on the severity of the condition administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Horses

Indication

The drug is indicated as an anti-inflammatory agent in horses.

Dosage

2.5 to 5 milligrams administered intravenously or intramuscularly. Dosage may be repeated if necessary.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Horse

Composition / specifications

Specifications: The drug is a sterile aqueous solution. Each milliliter contains 4.0 milligrams of dexamethasone sodium phosphate (equivalent to 3.0 milligrams of dexamethasone).

Dogs

Indication

The drug is given for glucocorticoid and anti-inflammatory agent.

Dosage

0.25 to 1 milligram initially, administered intravenously. May be repeated for 3 to 5 days or until response is noted.

Limitations

Horses

Indication

The drug is given for glucocorticoid and anti-inflammatory agent.

Dosage

2.5 to 5 milligrams administered intravenously.

Limitations

If permanent glucocorticoid effect is required, oral therapy may be substituted. When therapy is to be withdraw after prolonged use, the daily dose should be reduced gradually over several days. Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis. Do not use in viral infections. Anti-inflammatory action of glucocorticoids may mask signs of infection. Except when used for emergency therapy, the product is contraindicated in animals with tuberculosis, chronic nephritis, cushingoid syndrome, or peptic ulcers. Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

In treatment of dogs as an anti-inflammatory agent. In treatment of cats as an anti-inflammatory agent. The drug is indicated for the treatment of primary bovine ketosis.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Cat Diarrhea (1) • Dog Decreased appetite (1) • Dog Appetite disorder NOS (1) • Dog

Showing top 5 for Digestive.

Neurologic

Unsteady walking (1) • Cat

Showing top 5 for Neurologic.

Behavior

Biting -aggression (1) • Dog Anxiety (1) • Dog

Showing top 5 for Behavior.

Other

Diabetic ketoacidosis (1) • Cat Diabetes mellitus (1) • Cat Dermatitis (1) • Dog Dermal thickening (1) • Cat Dehydration (1) • Dog

Show more (20)

Decreased pulse oxygenation (1) • Dog Decreased bowel movements (1) • Cat Decreased blood urea nitrogen (BUN) or creatinine (1) • Dog Death (1) • Dog Deafness (1) • Cat Constricted pupils (1) • Dog Circulatory collapse (1) • Dog Blood in urine (1) • Dog Balance problem (1) • Cat Azotaemia (1) • Cat Aspiration pneumonia (1) • Dog Arthritis (1) • Dog Anaphylaxis (1) • Dog Anal sac disorder (1) • Dog Anaemia NOS (1) • Dog Agglutination test, positive (1) • Dog Addison's disease (1) • Dog Abnormal ultrasound finding (1) • Cat Abnormal radiograph finding (1) • Dog Abnormal cytology (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shih Tzu, Female, 16 week, 2.49 kilogram • Drug: MSK, Parenteral • Reactions: Facial swelling (possible allergy), Vomiting • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014246
Serious AE: No
Treated For AE: No
Sex: Female
Age: 16.00 Week
Weight: 2.490 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Parenteral

Reactions Reported:

Facial swelling (possible allergy) Vomiting

Outcomes: Outcome Unknown

Cat, Siamese, Male, 10 year, 5.65 kilogram • Drug: MSK, Unknown • Reactions: Lack of efficacy - NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014239
Serious AE: No
Treated For AE: No
Sex: Male
Age: 10.00 Year
Weight: 5.650 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Lack of efficacy - NOS

Outcomes: Outcome Unknown

Cat, Domestic Shorthair, Female, 18 year, 3.3 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Gait abnormality, Walking difficulty, Decreased appetite • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-013996
Serious AE: No
Treated For AE: No
Sex: Female
Age: 18.00 Year
Weight: 3.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Gait abnormality Walking difficulty Decreased appetite

Outcomes: Ongoing

Dog, ['Retriever - Labrador', 'Poodle (unspecified)'], Female, 8.08 year, 11.7 kilogram • Drug: MSK, Auricular (Otic) • Reactions: Hypoalbuminaemia, Neutropenia • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2026-US-014100
Serious AE: No
Treated For AE: No
Sex: Female
Age: 8.08 Year
Weight: 11.700 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Auricular (Otic)

Reactions Reported:

Hypoalbuminaemia Neutropenia

Outcomes: Outcome Unknown

Cat, Domestic Longhair, Female, 7 year, 4.47 kilogram • Drug: MSK, Unknown, Frequency: 3 per day • Reactions: Localised hair loss, Reddening of the skin, Itchy skin, Wound, Dermal thickening… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-013537
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 7.00 Year
Weight: 4.470 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Frequency: 3 per day

Reactions Reported:

Localised hair loss Reddening of the skin Itchy skin Wound Dermal thickening Abnormal cytology Intentional misuse Local swelling Reverse sneezing Leukocytosis NOS Thrombocytopenia Neutrophilia Monocytosis Skin lesion NOS

Outcomes: Ongoing

Dog, Bulldog - French, Female, 7 year, 12.791 kilogram • Drug: MSK, Solution/drops, Unknown • Reactions: Tiredness (lethargy), Decreased appetite, Limping, Fever, Swollen lymph node… • Outcome: Ongoing

Report ID: USA-USFDACVM-2026-US-012576
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 7.00 Year
Weight: 12.791 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Solution/drops

Reactions Reported:

Tiredness (lethargy) Decreased appetite Limping Fever Swollen lymph node Weight loss Polyuria Polydipsia Vomiting Nasal discharge Laboured breathing Stridor Gait abnormality Joint pain Joint effusion Immune-mediated polyarthritis Lymphopenia Hypoalbuminaemia Elevated globulins Elevated aspartate aminotransferase Elevated serum alkaline phosphatase

Outcomes: Ongoing

Dog, Shar Pei, Female, 11 year, 32.7 kilogram • Drug: MSK, Unknown • Reactions: Arthritis, Decreased appetite, High sodium-potassium ratio, Vomiting, Diarrhea… • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2026-US-012110
Serious AE: No
Treated For AE: Yes
Sex: Female
Age: 11.00 Year
Weight: 32.700 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Arthritis Decreased appetite High sodium-potassium ratio Vomiting Diarrhea Gait abnormality Appetite disorder NOS Stiffness NOS Not defecating Weight loss Dysorexia Hair loss NOS Weakness Muscle wasting Distension of abdomen Polyuria Dehydration Shaking Shivering Tremors Greasy skin Hair shedding Anxiety

Outcomes: Recovered/Normal

Dog, Dachshund (unspecified), Female, 12 year, 7.62 kilogram • Drug: MSK, Unassigned, Intramuscular • Reactions: Vomiting, Lack of efficacy - NOS • Outcome: Recovered/Normal

Report ID: USA-USFDACVM-2026-US-012730
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 12.00 Year
Weight: 7.620 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Intramuscular
Form: Unassigned

Reactions Reported:

Vomiting Lack of efficacy - NOS

Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Dexamethasone

Data freshness

Dexamethasone

Medication Snapshot

Dexamethasone

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

USA-USFDACVM-2026-US-014246

USA-USFDACVM-2026-US-014239

USA-USFDACVM-2026-US-013996

USA-USFDACVM-2026-US-014100

USA-USFDACVM-2026-US-013537

USA-USFDACVM-2026-US-012576

USA-USFDACVM-2026-US-012110

USA-USFDACVM-2026-US-012730

USA-USFDACVM-2026-US-011643

USA-USFDACVM-2026-US-011341

USA-USFDACVM-2026-US-009056

USA-USFDACVM-2026-US-008346

USA-USFDACVM-2026-US-011611

USA-USFDACVM-2026-US-005003

USA-USFDACVM-2026-US-005800

USA-USFDACVM-2026-US-003405

USA-USFDACVM-2026-US-001079

USA-USFDACVM-2025-US-075387

USA-USFDACVM-2025-US-074361

USA-USFDACVM-2025-US-074459

USA-USFDACVM-2025-US-074693

USA-USFDACVM-2025-US-074149

USA-USFDACVM-2025-US-073798

USA-USFDACVM-2025-US-071120

USA-USFDACVM-2025-US-070459

USA-USFDACVM-2025-US-068758

USA-USFDACVM-2025-US-070899

USA-USFDACVM-2025-US-069329

USA-USFDACVM-2025-US-067552

Grouped by Body System

Most Reported Reactions

Source Documents

Owner handouts

Official label / PI

SPL

FOI

Dexium-SP™

Dexium-SP™

Horses

Dexamethasone Solution

Dexamethasone Solution

Cattle

Horses

Zonometh Solution

Zonometh Solution

Dogs

Cats

Horses

Dexameth-A-Vet

Dexameth-A-Vet